NCT04679545Unknown2 期
A Randomized, Double-Blind, Placebo-Controlled Trial Using Cannabidiol for the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet
Pure Green1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2020年12月10日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Incidence of treatment-related adverse events as assessed by CTCAE v4.0
研究概览
简要总结
The purpose of the study is to evaluate whether PG-DN-20WS is a better pain reliever in patients with diabetic neuropathic pain of the feet than a placebo.
详细描述
Subjects will be enrolled in the study for a maximum of 43 days, including an optional 14-day screening period, 28 days of active product administration, and followed by a post-treatment follow-up within 1 day.
The primary objective of this study is:
- To evaluate the safety of PG-DN-20WS for the treatment of painful DPN of the feet compared to a placebo control, including emergence of suicidal thoughts.
The secondary objectives of this study are:
- To evaluate the impact of PG-DN-20WS on subject's neuropathic pain, anxiety, and sleep quality compared to a placebo control.
- To evaluate the impact of PG-DN-20WS on the subject's impression of their response to the treatment compared to a placebo control.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
盲法说明
Subjects will be randomized at a 1:1 ratio.
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is at least 21 years of age;
- •Subject has a diagnosis of diabetic neuropathic pain of the feet determined by the subject's primary care physician or related health care provider.
- •Subject has a mean pain scale score of ≥ 5 recorded in the 7 days prior to randomization.
- •If female, the subject is postmenopausal (> 1 year), surgically sterile (> 3 months), had a hysterectomy, or is currently using 2 effective forms of birth control.
- •Subject has not taken marijuana (cannabis) in any form, chemicals or extracts or foods or beverages or topical creams, lotions, gels, patches containing marijuana (cannabinoids, or and cannabis derivatives) including synthetic marijuana and/or CBD for at least 14 days prior to this study, and agrees to not take marijuana (cannabis) in any form, chemicals or extracts or foods or beverages or topical creams, lotions, gels, patches containing marijuana (cannabinoids, or and cannabis derivatives) including synthetic marijuana and/or CBD while participating in this study.
- •If subject is currently taking gabapentin, pregabalin, or duloxetine, subject must be willing to and completes a 7-day washout of these medications prior to randomization.
- •Subject has not taken any NSAIDs and/or acetaminophen for at least 2 days prior to randomization.
- •Subject is willing to provide his/her written informed consent to participate in the study as stated in the informed consent document.
- •Subject is willing to use an electronic diary to enter trial information for 29 days.
排除标准
- •Subject is pregnant or lactating;
- •Subject has an allergy to cannabis, the Cannabaceae plant family (e.g., hemp, hops), palmitoylethanolamide, or terpenes;
- •Subject has a known allergy to active or inert ingredients of the investigational product;
- •Subject is taking a concomitant medication or treatment that would complicate use or interpretation of the study drug's effects (examples include: Cannabis or any cannabinoid products; Any drug or herbal product that influences the endocannabinoid system (ECS));
- •Subject is taking marijuana (cannabis) in any form, chemicals or extracts or foods or beverages or topical creams, lotions, gels, patches containing marijuana (cannabinoids, or and cannabis derivatives) including synthetic marijuana and/or CBD for at least 14 days prior to this study, and does not promise that they will not take marijuana (cannabis) in any form, chemicals or extracts or foods or beverages or topical creams, lotions, gels, patches containing marijuana (cannabinoids, or and cannabis derivatives) including synthetic marijuana and/or CBD while participating in this study;
- •Subject currently resides in the state of Nebraska, Idaho, Iowa, or South Dakota.
- •Subject is currently being treated with antibiotics for sinus, throat, or lung infections;
- •Subject has shortness of breath associated with allergies;
- •Subject has uncontrolled asthma;
- •Subject has a fever and/or productive cough;
- •Subject has unstable angina, uncontrolled hypertension;
- •Subject currently or has a history of congestive heart failure;
- •Subject has any other unstable medical condition;
- •Subject has a personal or family history of schizophrenia;
- •Subject has a personal history or currently has suicidal ideation or attempted suicide;
- •Subject has a major neurological disorder, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, history of traumatic brain injury/head injury, and seizures.
- •Subject has taken pharmaceutical pain medicine of any kind, or has taken a NSAID and/or acetaminophen, within 2 days of randomization.
- •Subject has taken gabapentin, pregabalin, or duloxetine within 7 days prior to randomization or is unwilling to stop these medications.
- •Subject has an allergy to, or has an intolerance to, NSAIDs or acetaminophen.
- •Subject is currently taking any form of opioids.
- •Subject has a history of substance or alcohol abuse.
- •Subject has clinically significant illness, including cardiovascular disorders.
- •Subject has any condition in which the investigator believes will confound the data of the study or could put the subject at risk of harm.
- •Subject does not have access to a smart phone or does not know how to use a smart phone application.
研究组 & 干预措施
CBD
Experimental
Subject will receive a 28-day supply of 20 mg CBD sublingual tablets to be taken 3 times a day for 28 days.
干预措施: CBD (Drug)
Placebo Control
Placebo Comparator
A placebo sublingual tablet to be taken three times a day for 28 days.
干预措施: Placebo (Drug)
结局指标
主要结局
Incidence of treatment-related adverse events as assessed by CTCAE v4.0
时间窗: Four Weeks
To evaluate the safety of PG-DN-20WS for the treatment of painful DPN of the feet compared to a placebo control assessed by Common Terminology Criteria For Adverse Events (CTCAE) v4.0.
次要结局
- Anxiety as assessed by the Zung Self-Rating Anxiety Scale (SAS)(Four Weeks)
- Subject's Response to Treatment as assessed by Patient's Global Impression of Change (PGIC)(Four Weeks)
- Pain as assessed by Numerical Pain Rating Scale (NPRS)(Four Weeks)
- Sleep Quality as assessed by Pittsburgh Sleep Quality Index (PSQI)(Four Weeks)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 TreatmentMedDRA version: 20.0Level: LLTClassification code 10001624Term: Alcoholic hepatitisSystem Organ Class: 100000004871Alcoholic hepatitisEUCTR2020-004534-38-DEDURECT Corporation300
进行中（未招募）
1 期
OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)IgA nephropathy (IgAN)EUCTR2018-000075-33-ESOmeros Corporation434
进行中（未招募）
不适用
A study of AMG 416 in the treatment of secondary hyperparathyroidism in chronic kidney diseaseEUCTR2012-002806-31-HUKAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)500
进行中（未招募）
1 期
A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)EUCTR2013-003713-18-ITMillennium Pharmaceuticals, Inc178
进行中（未招募）
不适用
A study of AMG 416 in the treatment of secondary hyperparathyroidism in chronic kidney diseaseSecondary hyperparathyroidism in subjects with chronic kidney diseaseMedDRA version: 17.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersMedDRA version: 17.0Level: LLTClassification code 10020706Term: Hyperparathyroidism NOSSystem Organ Class: 10014698 - Endocrine disordersEUCTR2012-002805-23-ATKAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)500